Researchers have discovered that IL-39 in Myasthenia Gravis (MG) serves as a potent indicator of disease severity. This novel cytokine, a member of the IL-12 family, appears to play a critical role in the immune-mediated pathology of the condition.

Moreover, a study conducted by Jia K and colleagues analyzed serum samples from 51 patients with acetylcholine receptor (AChR) antibody-positive MG. They compared these to 43 healthy controls to establish a baseline for comparison. The results showed that active MG patients had significantly higher IL-39 levels than healthy individuals.

Clinical utility of IL-39 in Myasthenia Gravis

Furthermore, the study found a strong positive correlation between IL-39 concentrations and clinical assessment tools like the MG-ADL score. Patients with more severe symptoms, categorized under higher MGFA classifications, consistently displayed elevated cytokine levels. Significantly, when patients achieved remission after immunotherapy, their IL-39 levels dropped sharply.

Consequently, this suggests that the cytokine could act as a longitudinal biomarker to monitor treatment efficacy in clinical settings. Overall, IL-39 offers high diagnostic accuracy, as shown by an area under the curve (AUC) of 0.922. Doctors may soon use this measurement to improve personalized care for MG patients.

How does IL-39 help in managing Myasthenia Gravis?

IL-39 levels correlate with disease activity scores. Doctors can use these measurements to determine the severity of the condition and monitor how well a patient responds to immunotherapy.

Can IL-39 distinguish MG patients from healthy individuals?

Yes, research shows that patients with active MG have significantly higher serum IL-39 levels compared to healthy controls, with a high diagnostic accuracy rate.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional healthcare. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Jia K et al. Elevated serum Interleukin-39 in Myasthenia gravis: a possible biomarker. Eur J Med Res. 2026 Mar 03. doi: 10.1186/s40001-026-04172-8. PMID: 41776695.


2. Ahmadi P et al. The role of IL-39 in autoimmune diseases: From general to immunopathogenesis. Cytokine. 2025;192:156969.


3. Lu Z et al. Interleukin 39: a new member of interleukin 12 family. Cent Eur J Immunol. 2020;45(2):214-217.